GLP-1 Weight Loss Drugs
Current trend: escalating · Category: Health · Last updated: August 16, 2026
Current situation
Demand continues expanding while manufacturers increase production capacity. This has ramped up as companies introduce pills instead of injections. Corporate insurance has been increasingly less generous in covering these treatments, even as evidence emerges that long-term costs are lower due to overall healthier participants. New evidence is emerging almost weekly that GLP-1s have promising side-effects, such as curbing alcohol addictions.
Why we're watching
These drugs could reshape healthcare costs, food consumption (and **types** of consumption), insurance, and labor productivity. Studies have shown relatively few side-effects, compared to sometimes stunning and unexpected benefits.
What to watch for next
Insurance coverage, Manufacturing capacity, Clinical trial results, Increased availability
Signal history
- 2026-08-16 — GLP-1s May Be Working in an Entirely Different Way Than We Thought Nobody **really** knows how these things work...they just do. New research suggests that GLP-1 drugs have a more complex mechanism of action in weight loss, not just suppressing the "hunger gene." The experiments were carried out in mice, not people, and female mice showed effects that male mice did not. Almost all studies show benefits for humans, but we don't yet really know how or why they work so well, and for conditions other than weight loss. So far, adverse side effects have been remarkably constrained.
- 2026-08-13 — Eli Lilly Sues Sellers of Black Market Weight-Loss Drugs The lawsuits claim the entities sell retatrutide, a GLP-1 drug that is still in trials and not yet approved by the FDA. **Bottom line, consumers needs to be careful about buying from black market "wellness clinics" that are prescribing drugs not approved for use, especially with costs coming down for approved on-label makers.**
- 2026-08-09 — Harvard study links GLP-1 weight-loss drugs to a 27-point jump in women's employment — bigger than a college degree In a paper published by the National Bureau of Economic Research, a Harvard economist found that women who were unemployed when they began taking GLP-1 medications saw a 27% increase in employment 18 months later compared with women who wanted to take the medications but had not yet started. **Bottom line, the study raises questions about whether changes in appearance may affect how women are perceived by employers**
- 2026-08-08 — Gastroparesis, Muscle Loss, Blindness — Ozempic Lawsuits Make Serious Claims Novo Nordisk, manufacturer of Ozempic, is facing lawsuits from patients who allege they developed gastrointestinal injuries after using GLP-1 medications. Similar lawsuits have also been filed against Eli Lilly. Research has also shown a possible association between the active ingredient in Ozempic, and a rare eye condition. The issue has gotten more attention lately due to a Joe Rogan podcast episode. **Bottom line, a casual relationship has not yet been established, and no legal precedents have yet been set.**
- 2026-08-06 — CVS Health enhances its direct-to-consumer weight management offerings At $29 per visit with no recurring membership or monthly fee, MinuteClinic’s care model is built to make a first step toward weight management straightforward and affordable. As one of the largest retail-facing providers, this is a big move by CVS and will likely be followed by Walmart, Amazon, and others.
- 2026-08-02 — Different GLP-1 therapies could be tailored to patients’ individual needs The potential to personalize GLP-1 therapies based on individual metabolic needs underscores a shift in obesity treatment that could improve outcomes by overall health. This emerging approach should lead to more effective treatments.
- 2026-07-30 — How to Get GLP-1s for $50 As of July 1, Medicare covers weight-loss drugs for the first time. Eligible beneficiaries can get Wegovy, Zepbound or Foundayo for $50 a month through the Medicare GLP-1 Bridge. You need a BMI > 27, there is an expiration date, and long-term coverage is questionable.
- 2026-07-30 — GLP-1 weight-loss drugs may cut drinking and alcohol cravings A new study has sparked excitement in the addiction-treatment community. The new research marks the first time a study has shown that people who were moderate to heavy drinkers and who were looking for solutions to their alcohol issues would benefit from an oral GLP-1.
- 2026-07-28 — They Used GLP-1s to Lose Weight. They Ended Up in Treatment for Anorexia. While GLP-1s have been hailed as miracle drugs, it can be dangerous for those who’ve struggled with restrictive eating and anorexia. Anorexia is the second most deadly mental illness after opioid addiction
- 2026-07-27 — 'There's going to be a lot of unexpected babies' GLP-1s may impact the speed of absorption of some oral medications, including birth control. There is some evidence that the pill can fail while women are on GLP-1s, leading to so-called ‘Ozempic babies'.
- 2026-07-26 — Millions of people are using GLP-1s...but what about their love lives Early research suggests the GLP-1s could suppress more than just hunger. Some patients have shared that they have experienced changes in desire, sexual function and emotional connection.
- 2026-07-24 — Eli Lilly Will File For Retatrutide Approval Retatrutide is considered likely the most powerful weight loss drug yet, as it targets multiple hormones that impact appetite and metabolism, instead of one or two. One study of adults with severe obesity showed an average weight loss of 22.6%, or 55.8 pounds, after 80 weeks.
- 2026-07-22 — GLP-1 drugs linked to 17% drop in worker sick leave GLP-1 drugs could lead to cost savings for workers and their employers by reducing employee sick leave. The study could be used by corporations to justify covering the cost of the drugs for workers.
- 2026-07-20 — America is embarking on a risky experiment with GLP-1s and aging Someone in their 70s may benefit as much from weight loss as a person in their 30s but may respond very differently to these drugs’ side effects.
- 2026-07-18 — Weight loss drugs may improve job prospects and dating odds A recent study suggests GLP-1 weight loss may improve some women’s relationships and employment status. Marriage and cohabitation rose 29% for single women after about 18 months. Job prospects rose 27%.